

# Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT

NCT06119256

---

Status	RECRUITING
Phase	Phase 1
Sponsor	Chinese PLA General Hospital
Enrollment	12 participants

## Key Eligibility Criteria

---

### Inclusion (3)

- Age 14-75 years, gender unlimited.
- Diagnosed with hematologic malignancies and have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT), with EBV infection after allo-HSCT.
- Karnofsky Score  $\geq 70$  (age  $\geq 16$ y) or Lansky Score  $\geq 50$  (age  $< 16$ y).

### Exclusion (9)

- Patients with uncontrolled active aGVHD one day before TCR-T cell infusion.
- Patients with severe kidney disease (Cr  $> 3 \times$  normal value), liver damage (TBIL  $> 2.5 \times$  upper limit of normal value, ALT and AST  $> 3 \times$  upper limit of normal value) or heart failure (NYHA heart function grade IV) one week before TCR-T cell infusion.
- Anticipated to take immunosuppressive hormones on the day of TCR-T cell infusion.
- Have other malignancies.
- Have relapsed and uncontrolled hematologic malignancies.
- ... and 4 more (see full listing online)

## Locations (1 total)

---

Chinese PLA General Hospital, Beijing, Beijing Municipality, China